Efficacy of Almonertinib Versus Osimertinib as the First‐Line Treatment for Non‐Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study

Ähnliche Einträge

• Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
  von: Yutaro Nagano, et al.
  Veröffentlicht: (2026)
• Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations
  von: Yuko Iida, et al.
  Veröffentlicht: (2026)
• First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
  von: Yugo Matsumura, et al.
  Veröffentlicht: (2025)
• Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
  von: Kei Sonehara, et al.
  Veröffentlicht: (2024)
• Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components
  von: Ying Li, et al.
  Veröffentlicht: (2024)